Barclays Reinstates an 'Overweight' Rating on Allscripts Healthcare (MDRX); Just What the Doctor Could Order
Tweet Send to a Friend
Barclays reinstates an 'Overweight' rating on Allscripts Healthcare (Nasdaq: MDRX), price target $23.
Barclays analyst says, "We are reinstating our ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "We are reinstating our ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
